| Subject: | FDA Issues Guidance for AntiViral Medication Stockpiles At or Nearing Expiration |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 6 Nov 2009 - 03:00 pm |
| During this H1N1-realted public health emergency, the Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) that expand access to medical products that may become necessary. Two antiviral treatments covered by Emergency Use Authorizations, Tamiflu (oseltamavir) and Relenza (zanamivir), may already be included in many emergency stockpiles. All companies, U.S. states and localities, and other organizations with Tamiflu and Relenza that are approaching, or... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
